CSL Releases First Corporate Responsibility Report; Highlights Access To Medicines, Environmental Impact And Compliance
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Melbourne-headquartered CSL March 29 released its first Corporate Responsibility Report, combining information about the company's economic, social and environmental performance for 2009
You may also be interested in...
Australia's CSL Gets TGA Green Light For Swine Flu Vaccine; Donates 10 Percent Of Supply To WHO
PERTH, Australia - One week after CSL announced that one dose of its swine flu vaccine Panvax was effective in staving off the A/H1N1 virus, the company received the green light from Australia's Therapeutic Goods Administration to register the product in Australia for use in people older than 10 years of age
Spilled Blood: CSL & Talecris Terminate Their Merger Deal In Face of FTC Lawsuit
Caving in to opposition from the Federal Trade Commission, CSL Limited has scuttled its $3.1 billion deal to acquire Talecris Biotherapeutics, saying it was not worth the money and time to battle the agency in court
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).